Plasma concentrations of tumor necrosis factor alpha may predict the outcome of patients with acute renal failure

Kidney and Blood Pressure Research

Volumn 29, Issue 4, 2006, Pages 203-209

  Ficek, Rafał ^a   Kokot, Franciszek ^a   Chudek, Jerzy ^a   Adamczak, Marcin ^a   Ficek, Joanna ^a   Wiȩcek, Andrzej ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Acute renal failure; Chronic renal failure; Hemodialysis; Tumor necrosis factor

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANURIA; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CONVALESCENCE; DISEASE CLASSIFICATION; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HOSPITAL DISCHARGE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OLIGURIA; OUTCOME ASSESSMENT; POLYURIA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SURVIVAL; URINARY EXCRETION;

ADULT; AGED; BIOLOGICAL MARKERS; FEMALE; HUMANS; KIDNEY; KIDNEY FAILURE, ACUTE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RENAL DIALYSIS; ROC CURVE; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33751169803     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000095734     Document Type: Article

References (21)

1. Balkwill FR: Tumour necrosis factor. Br Med Bull 1988;45:389-400.
2. Renick DG: Significance of in vivo detection of tumor necrosis factor. Clin Invest 1991;65:259-261.
3. Feldmann M, Brennan M, Elliott MJ, Williams RO, Maini RN: TNF alpha is an effective therapeutic target for rheumatoid arthritis. Ann NY Acad Sci 1995;766:272-279.
4. Pereira BJG, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA: Plasma levels of IL-1β, TNFα and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int 1994;45:890-896.
5. Cappelli G, DiFelice A, Perrone S, Bonucchi D, Savazzi AM, Ciuffreda A, Lusvarghi E: Which level of cytokine production is critical in haemodialysis? Nephrol Dial Transplant 1998;13(suppl 7):55-60.
6. Kimmel PL, Chawla LS, Amarasinghe A, Peterson RA, Weihs KL, Simmens SJ, Alleyne S, Burke HB, Cruz I, Veis JH: Anthropometric measures, cytokines and survival in haemodialysis patients. Nephrol Dial Transplant 2003;18:326-332.
7. Shulman LM, Yuhas Y, Frolkis I, Gavendo S, Knecht A, Eliahou HE: Glycerol induced ARF in rats is mediated by tumor necrosis factor-alpha. Kidney Int 1993;43:1397-1401.
8. Ramesh G, Reeves WB: Inflammatory cytokines in acute renal failure. Kidney Int 2004;66(suppl 91):S56-S61.
9. Daemen MA, van de Ven MW, Heineman E, Buurman WA: Involvement of endogenous interleukin-10 and tumor necrosis factor-alpha in renal ischemia-reperfusion injury. Transplantation 1999;67:792-800.
10. Knotek M, Rogachev B, Wang W, Ecder T, Melnikov V, Gengaro PE, Esson M, Edelstein CL, Dinarello CA, Schrier RW: Endotoxemic renal failure in mice: role of tumor necrosis factor independent of inducible nitric oxide synthase. Kidney Int 2001;59:2243-2249.
11. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644-1655.
12. Levey AS, Greene T, Kusek JW, Beck G: A simplified equation to predict glomerular filtration rate from serum creatinine (abstract). J Am Soc Nephrol 2000;11:A0828.
13. Herbelin A, Nguyen AT, Zingraff J, Urena P, Descamps-Latscha B: Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor alpha. Kidney Int 1990;37:116-125.
14. Kimmel PL, Phillips TM, Simmens SJ, Peterson RA, Weihs KL, Alleyne S, Cruz I, Yanovski JA, Veis JH: Immunologic function and survival in hemodialysis patients. Kidney Int 1998;54:236-244.
15. Pertosa G, Grandaliano G, Gesualdo L, Schena FP: Clinical relevance of cytokine production in hemodialysis. Kidney Int 2000;58(suppl 76):S104-S111.
16. Byrick RJ, Goldstein MB, Wong PY: Increased plasma tumor necrosis factor concentration in severe rhabdomyolysis is not reduced by continuous arteriovenous hemodialysis. Crit Care Med 1992;20:1483-1486.
17. Iglesias J, Marik PE, Levine JS: Elevated serum levels of the type I and type II receptors for tumor necrosis factor-α as predictive factors for ARF in patients with septic shock. Am J Kidney Dis 2003;41:62-75.
18. Simmons EM, Himmelfarb J, Sezer MT, Chertow GM, Mehta RL, Paganini EP, Soroko S, Freedman S, Becker K, Spratt D, Shyr Y, Ikizler TA; PICARD Study Group: Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int 2004;65:1357-1365.
19. Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G, Wunderink R, Dal Nogare A, Nasraway S, Berman S, Cooney R, Levy H, Baughman R, Rumbak M, Light RB, Poole L, Allred R, Constant J, Pennington J, Porter S: Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 1998;351:929-933.
20. Bellomo R, Tipping P, Boyce N: Continuous veno-venous hemofiltration with dialysis removes cytokines from the circulation of septic patients. Crit Care Med 1993;21:522-526.
21. Bonventre JV, Zuk A: Ischemic acute renal failure: an inflammatory disease? Kidney Int 2004;66:480-485.